Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|MS023||MS023 inhibits type I protein arginine methyltransferases (PRMTs), which may lead to anti-tumor activity (PMID: 26598975).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|KMT2A - MLLT3 SRSF2 P95H||acute myeloid leukemia||sensitive||MS023||Preclinical||Actionable||In a preclinical study, MS023 inhibited survival of murine KMT2A-MLLT3 ( reported as MLL-AF9)-driven acute myeloid leukemia cells harboring SRSF2 P95H in culture and delayed disease progression in mouse models, but not in wild-type SRSF2 models (PMID: 31408619).||31408619|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|